[Clinical and metabolic effects of recombinant human growth hormone in cardiac insufficiency].
Growth hormone (GH) acting through locally produced insulin--like growth factors stimulates myocardial hypertrophy and increases myocyte contractility. Many people with growth hormone deficiency (GHD) present a lower left ventricular mass, reduced ejection fraction and lower exercise tolerance. Recombinant human growth hormone (rhGH) administration gives a chance to correct these disturbances. On the other hand excessive levels of GH (for example in acromegaly) may induce heart failure too. Initially, cardiac hypertrophy is an adaptive response, but with time, in untreated cases, it leads to congestive heart failure. Mentioned information inclined many authors to undertake researches on rhGH application in severe heart failure in patient with idiopathic dilated cardiomyopathy and coronary disease. RhGH improved treatment let these patients reach heart transplantation.
Zakład Medycyny Paliatywnej przy Katedrze Medycyny Rodzinnej Akademii Medycznej w Gdańsku.
Aleksandra
A
Modlińska
Anna
A
Babińska
Grzegorz
G
Faran
Krzysztof
K
Sworczak
D000172:Acromegaly / Q000139:chemically induced; D013006:Growth Hormone / Q000009:adverse effects*; D006333:Heart Failure / Q000139:chemically induced*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000378:metabolism
D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone